IMO it would be unlikely that any of the Tiblisi cohort would be part of the FDA application. I am not sure that Tiblisi would be considered gold standard. They would be included as secondary supporting documentation only....compelling and integral to the proof of concept confirmation, yes, but still secondary.
AVR Price at posting:
$29.30 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)